Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Boehringer Ingelheim Corporation Stories

2013-11-02 08:21:34

Multiple studies presented at The Liver Meeting® investigating faldaprevir include difficult-to-cure patient populations, such as those with HIV/HCV coinfection and advanced liver disease RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data from its Phase 3 clinical trial program, STARTVerso(TM), which evaluates the investigational protease inhibitor, faldaprevir, in combination with pegylated interferon and ribavirin...

2013-11-02 08:21:30

Clinical trial studies an all-oral, 12-week regimen containing the investigational compounds faldaprevir, deleobuvir, and Presidio Pharmaceuticals' PPI-668 with and without ribavirin in 36 difficult-to-treat genotype-1a HCV patients RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim data from its Phase 2a hepatitis C (HCV) clinical collaboration (NCT01859962) with Presidio Pharmaceuticals, Inc. that showed all patients (13/13)...

2013-10-28 08:29:11

Phase 2 and Phase 3 data presented at the 2013 American College of Chest Physicians (ACCP) annual meeting RIDGEFIELD, Conn., Oct. 28, 2013 /PRNewswire/ -- Boehringer Ingelheim today presented the latest data for tiotropium in asthma at the 2013 American College of Chest Physicians (ACCP) annual meeting (CHEST 2013) in Chicago. The CHEST session "Tiotropium and Asthma" features a total of four oral presentations from Phase 2 and 3 studies of tiotropium delivered via the...

2013-10-24 16:27:17

Eleven presentations on investigational compounds and an approved product will be presented at the CHEST 2013 meeting RIDGEFIELD, Conn., Oct. 24, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced the upcoming presentation of data from 11 abstracts, including 6 oral presentations, across the company's respiratory portfolio at the 2013 American College of Chest Physicians (ACCP) annual meeting, CHEST 2013, taking place October 26 - 31 in Chicago. These data exemplify...

2013-10-09 12:26:15

Conference brings together Daughters from across the United States to build awareness of devastating disease CULVER CITY, Calif., Oct. 9, 2013 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is pleased to announce the first ever Daughters of Pulmonary Fibrosis Leadership Conference to be held at the Marriott Marquis in downtown Atlanta, Friday, October 11 to Saturday, October 12. This unique program will bring together relatives of past and present patients with idiopathic...

2013-10-08 08:28:26

Collaborative trial from Boehringer Ingelheim and Presidio Pharmaceuticals investigates triple-DAA regimen of faldaprevir, deleobuvir and PPI-668 RIDGEFIELD, Conn., Oct. 8, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that interim data from its Phase 2 hepatitis C (HCV) clinical collaboration (NCT01859962) with Presidio Pharmaceuticals have been accepted as a late breaker poster presentation at the 64th Annual Meeting of the American Association for the...

2013-10-02 23:24:34

Visible Health and BIPI collaborate to deliver updated drawMD Cardiology patient education iPad app. Austin, Texas (PRWEB) October 02, 2013 Visible Health announced today a collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. to sponsor the popular drawMD Cardiology patient education app for the iPad. The drawMD app for the iPad allows doctors to create visual images that can be used to guide conversations about medical and surgical conditions and procedures with their patients....

2013-10-02 08:30:57

Data published in Circulation show trend towards lower mortality, despite the lack of a specific reversal agent for dabigatran RIDGEFIELD, Conn., Oct. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a retrospective analysis comparing clinical management and patient outcomes following a major bleeding event during treatment with dabigatran or warfarin. The findings show that outcomes after a major bleed on dabigatran were not worse than after a...

2013-10-01 12:30:34

RIDGEFIELD, Conn., Oct. 1, 2013 /PRNewswire/ -- New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program have been accepted for presentation at the 64(th) Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(®), taking place November 1-5 in Washington, D.C. Presentations will include data from several studies evaluating Boehringer Ingelheim's investigational compound, faldaprevir,...

2013-09-24 12:28:28

NEW YORK, Sept. 24, 2013 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim and the Coalition for Pulmonary Fibrosis (CPF) are teaming up to raise awareness of idiopathic pulmonary fibrosis, or IPF, a progressive and fatal disease that causes permanent scarring of the lungs, difficulty breathing, and prevents oxygen from getting to the body. This collaboration also features actress Rose McGowan, who is best known for her leading role in the hit...